Compared with placebo, dupilumab treatment resulted in statistically significant and meaningful symptom improvements in adults and adolescents with eosinophilic esophagitis (EoE), according to ...
Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important drivers of atopic or ...
Two abstracts presented at the American Thoracic Society 2024 International Conference analyzed the phase 3 LIBERTY COPD BOREAS trial, finding that dupilumab improves pre- and post-bronchodilator lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback